Categories: Health

Virbac : Declaration of the number of share and voting rights 05/2025

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS

Information on the total number of voting rights and of shares representing the share capital
(Article 223-16 of the General regulations of the French Financial Market Authority – Autorité
des Marchés Financiers)

Quotation place: Euronext Paris
Compartiment A
ISIN code: FR0000031577

Date Total number of shares representing the share capital Total number of voting rights
May, 31 2025 8 390 660 Gross total of voting rights : 12 705 976
Net total* of voting rights : 12 693 140

Net total* = total number of voting rights attached to the total number of shares net of shares with no voting rights.

VIRBAC: Shaping the future of animal health
NYSE Euronext – Compartiment A / Code ISIN: FR0000031577 / MNEMO: VIRP
Corporate Finance: tel. 33 4 92 08 71 32 / Email: finances@virbac.com
Website: www.virbac.com

GlobeNews Wire

Recent Posts

Hyundai Motor Group Showcases Hydrogen Technologies Across the Value Chain at World Hydrogen Expo in Korea

Hyundai Motor Group, together with its 7 affiliates, highlights cutting-edge hydrogen technologies and real-world applications…

9 minutes ago

Spectacular celebrations as the Olympic flame arrives in Italy ahead of the Olympic Winter Games Milano Cortina 2026

05 December 2025 - Celebrations have taken place in Rome to mark the arrival of the…

10 minutes ago

14th Olympic Summit on 11 December 2025 Information for the media

05 December 2025 - The International Olympic Committee (IOC) will host the 14th Olympic Summit on…

10 minutes ago

CocaCola music festival set to ignite Olympic Torch Relay celebrations in Rome

05 December 2025 - As the Olympic flame prepares to begin its journey through Italy ahead…

10 minutes ago

Godrej Industries Group’s Assistive Tech Conference promotes accessible and equitable workplaces in India

MUMBAI, India, Dec. 6, 2025 /PRNewswire/ -- Godrej Industries Group recently hosted its inaugural Assistive…

1 hour ago

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab…

3 hours ago